MacroGenics (M55) AI Stock Analysis

MacroGenics

(Frankfurt:M55)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

MGC026 clinical progressMGC026 has demonstrated durable antitumor activity across multiple tumor types, giving MacroGenics a potentially differentiated clinical asset. The planned expansion and pembrolizumab combination study could broaden development opportunities if the early efficacy and safety profile are sustained.

Negative Factors

Persistent cash burnNegative operating and free cash flow show that the business is not yet funding operations internally. Continued cash consumption may require additional financing or collaboration proceeds, potentially limiting strategic flexibility and creating funding dependence until profitability is achieved.

MacroGenics (M55) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 152.88M
Dividend Yield: ―
Average Volume (3M): 2,684
Price to Earnings (P/E): -10.9
Beta (1Y): 0.45
Revenue Growth: -4.85%
EPS Growth: 63.70%
Country: Germany
Employees: 293
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

MacroGenics Business Overview & Revenue Model

Company Description

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a...

MacroGenics Earnings Call Summary

Earnings Call Date:Mar 19, 2025(Q4-2024)|% Change Since:4.58%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentNeutral

MacroGenics achieved significant clinical and financial milestones in 2024, marked by a substantial increase in revenues and strong progress in clinical trials. However, increased net losses and operating expenses, along with the discontinuation of vobra duo, present challenges. The company remains financially stable with a solid cash position and is poised for future growth.

Positive Updates

Significant Revenue Growth

MacroGenics reported a total revenue of $150 million for the year ended December 31, 2024, compared to $58.7 million in 2023, primarily due to milestones achieved under the Incyte License Agreement.

Negative Updates

Increased Net Loss

MacroGenics reported a net loss of $67 million for the year ended December 31, 2024, compared to $9.1 million in 2023, due to increased R&D expenses and other operational costs.

Company Guidance

In the conference call, MacroGenics provided guidance and updates on their financial and clinical developments for the year 2024 while highlighting expectations for 2025. The company reported a total revenue of $150 million for 2024, a significant increase from $58.7 million in 2023, largely due to milestone achievements under the Incyte License Agreement. Research and development expenses rose to $177.2 million, up from $166.6 million in the previous year, reflecting increased costs related to their ADC pipeline and clinical trials. Cash, cash equivalents, and marketable securities totaled $201.7 million at the end of 2024, ensuring a cash runway into the second half of 2026. Clinically, MacroGenics provided updates on their investigational therapies, including the completion of enrollment in the 150-patient LORIKEET Phase 2 trial for lorigerlimab and plans to initiate the LINNET Phase 2 study in mid-2025. Additionally, three ADC molecules are in various stages of development, with MGC026 and MGC028 in clinical trials and MGC030 in preclinical studies. The company is also advancing MGD024, a bi-specific DART molecule, with ongoing Phase 1 studies.

MacroGenics Risk Analysis

MacroGenics disclosed 49 risk factors in its most recent earnings report. MacroGenics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.We may undertake internal restructuring activities, including associated workforce reductions, that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.Q4, 2023

2.If our information technology systems or those third parties upon which we rely for our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.Q4, 2023

3.We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers; and other adverse business consequences.Q4, 2023

MacroGenics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:M55 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATOS	54Neutral	$21.66M	-0.50	-102.99%	―	―	-28.83%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORMP	51Neutral	$170.97M	0.97	72.96%	―	-100.00%	―
ANIX	49Neutral	$108.46M	-10.23	-70.44%	―	―	10.04%
SRZN	49Neutral	$341.32M	-0.71	187.62%	―	-8.79%	-195.46%
SEER	41Neutral	$93.02M	-1.38	-27.23%	―	-13.23%	12.29%

* Healthcare Sector Average

Performance Comparison

DE:M55 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:M55	MacroGenics Inc	2.10	0.68	47.99%
ATOS	Atossa Therapeutics, Inc.	2.17	-10.78	-83.24%
ORMP	Oramed Pharmaceuticals Inc	4.11	1.91	86.82%
ANIX	Anixa Biosciences	3.12	-1.02	-24.64%
SEER	Seer, Inc.	1.68	-0.59	-25.99%
SRZN	Surrozen, Inc.	29.04	15.98	122.36%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

MacroGenics AI Stock Analysis